Single administrations of GITRL-FP at 5 and 1 mg/kg resulted in prevention of tumor outgrowth or complete regression of CT26 tumors up to day 30 in all but one mouse (Fig. 1a). This evidence concerns the gene TNFSF18 and neoplasm.